UK pharma shifts as Merck and AstraZeneca scale back: can CDMOs fill the gap?
Recent major site withdrawals and investment pauses have raised concerns about the UK’s industrial strength. But CDMOs say agility, innovation and technical expertise could redefine how and where drugs are made